Free Trial

Anixa Biosciences 9/6/2024 Earnings Report

Anixa Biosciences logo
$2.53 -0.21 (-7.66%)
(As of 12/18/2024 05:26 PM ET)

Anixa Biosciences EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Anixa Biosciences Earnings Headlines

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

View Anixa Biosciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings